Canadian Biotech Industry Offers Solutions to Global Marketplace

BOSTON & OTTAWA, Ontario--()--The Canadian biotechnology sector is a great example of how research, innovation and entrepreneurship within a healthy ecosystem can produce some truly remarkable innovations and companies with enormous potential to fundamentally change lives and economies.

Canada’s biotechnology sector is composed of many early stage companies that are expecting significant growth in the future. A recent study by Deloitte surveyed more than 200 biotech companies located in Canada. Business development priorities for most Canadian biotech companies includes attracting investment/competing for dollars, recruiting talent and scaling operations (source: Deloitte). Biotech companies give credit for key government programs including SR&ED, IRAP and provincial funded programs as key to establishing and growing operations in Canada (source: Deloitte)

“With over 900 Canadians from across the country attending BIO, Canada remains the largest international delegation at the annual industry convention. Importantly, through the BIOTECanada cost saving initiative, more than 100 small and medium sized BIOTECanada member companies were able to take advantage of significant savings on BIO registration and passes to the business partnering forum,” commented Andrew Casey President and CEO BIOTECanada.

Canadian programming highlights at booth #651 include:

Tuesday June 5, 2018
10:30am - Canada Pavilion Opening
1:30pm - National Panel on Accelerators and Incubators
Accelerators and incubators offer a receptor capacity for the recent federal investments in science programs turning ideas into Canadian companies. Panelists will offer their unique perspective aimed at building on existing expertise in 21st century technologies with a skilled labor force, creating innovation hubs and incentivizing investment, all intended to compete in the global marketplace of discovery and commercialization.

Moderated by:
John Knubley, Deputy Minister of Innovation, Science and Economic Development

Panel participants include:
Rory Francis, Executive Director PEI BioAlliance
Rafi Hofstein, President and CEO MaRS Innovation
Don Olds, President and CEO NEOMED
Gord McCauley, President and CEO CDRD (Centre for Drug Research and Development)
Nadine Beauger, CEO of IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research)

4pm – Canadian Hospitality Reception presented by IRICoR

Wednesday June 6, 2018
10:30am - BIOTECanada, Accel-Rx and Wilson Sonsini Goodrich & Rosati present the Annual Coast to Coast Competition. The Coast to Coast competition held on the stage at the Canadian pavilion (booth #651) is an opportunity where 4-5 companies from across Canada present to a judging panel of key life science investors. Representatives from Versant Ventures, CTI Life Sciences, Teralys Capital, CQDM, Accel-Rx, Wilson Sonsini Goodrich & Rosati. The successful company pitch will win a coveted presentation spot during BIOTECanada’s Investor Summit held in Whistler March 2019.
The following companies will be presenting:
Corbin Therapeutics
Kane Biotech
Neomed Therapeutics 1
PhotoDynamic, Inc.
ImmunobioChem

Contacts

BIOTECanada
Nadine Lunt, 613-230-5585 x257

Contacts

BIOTECanada
Nadine Lunt, 613-230-5585 x257